Furthermore, the mammalian target of rapamycin (mTOR), one of the major downstream effectors of the PI3K/AKT pathway, which implicates cell proliferation, migration, differentiation, and protein synthesis, was also examined as a target in PAH therapeutics. This evidence concerns the gene AKT1 and pulmonary arterial hypertension.